Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. (Q36068458)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15762051%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

review article

1 reference

title

Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15762051%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15762051%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

S Giannini

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15762051%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

M Serio

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15762051%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

publication date

1 November 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15762051%20AND%20SRC:MED&resulttype=core&format=json

Journal of Endocrinological Investigation

9 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15762051%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15762051%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15762051%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

982-991

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15762051%20AND%20SRC:MED&resulttype=core&format=json

Troglitazone and related compounds: therapeutic potential beyond diabetes

9 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Peroxisomal proliferator-activated receptor-gamma upregulates glucokinase gene expression in beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Prostaglandin D(2), its metabolite 15-d-PGJ(2), and peroxisome proliferator activated receptor-gamma agonists induce apoptosis in transformed, but not normal, human T lineage cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

PPAR and immune system--what do we know?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Nonhypoglycemic effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

PPARgamma and atherosclerosis: effects on cell growth and movement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

The role of the novel adipocyte-derived hormone adiponectin in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Role of oxidized low density lipoprotein in atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Activators of the nuclear receptor PPARgamma enhance colon polyp formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

PPAR-gamma receptor ligands: novel therapy for pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Antihypertensive effects of CS-045 treatment in obese Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Dualism of oxidized lipoproteins in provoking and attenuating the oxidative burst in macrophages: role of peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Protein kinase C activation and the development of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Decreased 5alpha-dihydrotestosterone catabolism suppresses T lymphocyte functions in males after trauma-hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

c-Fos-driven transcriptional activation of transforming growth factor β-1: inhibition of high glucose-induced promoter activity by thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Rosiglitazone reduces urinary albumin excretion in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Response of experimental retinal neovascularization to thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Cloning of adiponectin receptors that mediate antidiabetic metabolic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347546

Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation.

21 January 2018

1 reference

12 December 2020

Peroxisome proliferator-activated receptors: nuclear control of metabolism

1 reference

12 December 2020

Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells

1 reference

12 December 2020

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

1 reference

12 December 2020

Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas

1 reference

12 December 2020

Genetic deletion of chemokine receptor CXCR3 or antibody blockade of its ligand IP-10 modulates posttransplantation graft-site lymphocytic infiltrates and prolongs functional graft survival in pancreatic islet allograft recipients

1 reference

12 December 2020

Differentiation and reversal of malignant changes in colon cancer through PPARgamma

1 reference

12 December 2020

Expression of peroxisome proliferator-activated receptor (PPAR)-gamma in human lung cancer

1 reference

12 December 2020

Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats

1 reference

12 December 2020

Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells.

1 reference

12 December 2020

Mechanisms of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery

1 reference

12 December 2020

Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide

1 reference

12 December 2020

Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2

1 reference

12 December 2020

Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production

1 reference

12 December 2020

Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences

1 reference

12 December 2020

Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells

1 reference

12 December 2020

Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells

1 reference

12 December 2020

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

1 reference

12 December 2020

Troglitazone, a new antidiabetic agent possessing radical scavenging ability, improved decreased skin blood flow in diabetic rats

1 reference

12 December 2020

Role for interferon-gamma inducible chemokines in endocrine autoimmunity: an expanding field.

1 reference

12 December 2020

PPAR-gamma decreases endometrial stromal cell transcription and translation of RANTES in vitro

1 reference

12 December 2020

Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications.

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells.

1 reference

12 December 2020

Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03347546

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15762051%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference